AKT1 and cancer: As shown in cancer cells, inhibition of EPC function by deguelin may result in part from the suppression of Akt pathways (Supplementary Figure 3) and the hypoxia-induced expressions of VEGF and CXCR4 (Supplementary Figure 4).